At Brexogen, we are developing biomacromolecule cargo-controlled exosome as a cell-free regenerative medicine. By using induced pluripotent stem cells derived mesenchymal stem cells and stem cell stimulation technologies, we control the biomacromolecule cargo potential and composition inside exosome.